Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo

Acta Pharmacologica Sinica

Volumn 34, Issue 10, 2013, Pages 1349-1358

  Shi, Jian ^a   Cao, Bei ^a   Zha, Wei Bin ^a   Wu, Xiao Lan ^a   Liu, Lin Sheng ^a   Xiao, Wen Jing ^a   Gu, Rong Rong ^a   Sun, Run Bin ^a   Yu, Xiao Yi ^a   Zheng, Tian ^a,c   Li, Meng Jie ^a   Wang, Xin Wen ^a   Zhou, Jun ^a   Mao, Yong ^a   Ge, Chun ^a   Ma, Ting ^a   Xia, Wen Juan ^a   Aa, Ji Ye ^a   Wang, Guang Ji ^a   Liu, Chang Xiao ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^c Jiangsu Police Institute   (China)

Author keywords

20(S) ginsenoside Rh2; Absorption; Drug interactions; Excretion; HIV protease inhibitors; P glycoprotein; Pharmacokinetics; Ritonavir; Tissue distribution

Indexed keywords

ELACRIDAR; GINSENOSIDE RH 2; RITONAVIR; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG FECES LEVEL; DRUG URINE LEVEL; EFFUSION; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER VEIN; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; TISSUE HOMOGENATE; URINARY EXCRETION;

ACRIDINES; ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; CHROMATOGRAPHY, LIQUID; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GINSENOSIDES; HIV PROTEASE INHIBITORS; HUMANS; INJECTIONS, INTRAVENOUS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MASS SPECTROMETRY; P-GLYCOPROTEIN; RATS; RATS, WISTAR; RITONAVIR; TETRAHYDROISOQUINOLINES; TISSUE DISTRIBUTION; VERAPAMIL;

EID: 84887390403     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.69     Document Type: Article

References (22)

1. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338: 1281-92. (Pubitemid 28216584)
2. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-3. (Pubitemid 28279721)
3. Martinez E, Domingo P, Galindo MJ, Milinkovic A, Arroyo JA, Baldovi F, et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004; 38: 1017-23. (Pubitemid 38457212)
4. Kitagawa I, Yoshikawa M, Yoshihara M, Hayashi T, Taniyama T. Chemical studies of crude drugs (1). Constituents of Ginseng radix rubra. Yakugaku Zasshi 1983; 103: 612-22. (Pubitemid 13027064)
5. Lai DM, Tu YK, Liu IM, Chen PF, Cheng JT. Mediation of beta-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Med 2006; 72: 9-13.
6. Wu N, Wu GC, Hu R, Li M, Feng H. Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128. Acta Pharmacol Sin 2011; 32: 345-53.
7. Fei XF, Wang BX, Tashiro S, Li TJ, Ma JS, Ikejima T. Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells. Acta Pharmacol Sin 2002; 23: 315-22. (Pubitemid 34266588)
8. Hwang JT, Kim SH, Lee MS, Yang HJ, Kim MJ, Kim HS, et al. Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte. Biochem Biophys Res Commun 2007; 364: 1002-8. (Pubitemid 350103699)
9. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594-601. (Pubitemid 28162914)
10. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999; 57: 1147-52. (Pubitemid 29171690)
11. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423-31. (Pubitemid 27169089)
12. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44: 190-4. (Pubitemid 27327076)
13. Zhang J, Zhou F, Wu X, Gu Y, Ai H, Zheng Y, et al. 20(S)-Ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions. Drug Metab Dispos 2010; 38: 2179-87.
14. Zhang J, Zhou F, Wu X, Zhang X, Chen Y, Zha BS, et al. Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells. Br J Pharmacol 2012; 165: 120-34.
15. Yang Z, Gao S, Wang J, Yin T, Teng Y, Wu B, et al. Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. Drug Metab Dispos 2011; 39: 1866-72.
16. Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res 1998; 15: 423-8. (Pubitemid 28175123)
17. Meaden ER, Hoggard PG, Newton P, Tjia JF, Aldam D, Cornforth D, et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 2002; 50: 583-8. (Pubitemid 35214800)
18. Lee LS, Wise SD, Chan C, Parsons TL, Flexner C, Lietman PS. Possible differential induction of phase 2 enzyme and antioxidant pathways by American ginseng, Panax quinquefolius. J Clin Pharmacol 2008; 48: 599-609. (Pubitemid 351503513)
19. Andrade AS, Hendrix C, Parsons TL, Caballero B, Yuan CS, Flexner CW, et al. Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. BMC Complement Altern Med 2008; 8: 50.
20. Denissen JF, Grabowski BA, Johnson MK, Buko AM, Kempf DJ, Thomas SB, et al. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos 1997; 25: 489-501. (Pubitemid 27209374)
21. Molimard M, Diquet B, Benedetti MS. Comparison of pharma-cokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004; 18: 399-411. (Pubitemid 39215352)
22. Lam JL, Benet LZ. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 2004; 32: 1311-6. (Pubitemid 39410918)